0NM7.LSE Virbac SA
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- 0.44%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.
Is 0NM7.LSE undervalued?
Graham numberThe Graham number of Virbac SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Virbac SA fundamental analysis
No fundamental analysis for Virbac SA yet.
Virbac SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Virbac SA
Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, the United States, Brazil, and the Pacific. The company offers Vikaly, a cat food designed for the management of feline chronic kidney disease; Prevexto that contains imidacloprid and flumethrin, providing long-lasting parasite protection collar for dogs and cats at risk of fleas, ticks, lice, and…
Full company profileVirbac SA financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Virbac SA annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 872M | 862M | 869M | 938M | 934M | - | - | - |
| Gross Profit | 386M | 375M | 418M | 462M | 456M | - | - | - |
| Operating Income | 69.0M | 58.0M | 65.0M | 98.0M | 186M | - | - | - |
| Net Income | 34.6M | -2.58M | 20.1M | 51.6M | 137M | - | - | - |
| Balance Sheet | ||||||||
| Total Assets | 1.42B | 1.28B | 1.27B | 1.32B | 1.11B | - | - | - |
| Total Liabilities | 944M | 841M | 812M | 805M | 489M | - | - | - |
| Shareholders' Equity | 474M | 436M | 460M | 518M | 623M | - | - | - |
| Cash & Short-term Investments | 48.5M | 48.4M | 62.8M | 93.7M | 182M | - | - | - |
| Total Debt | 434M | 409M | 375M | 331M | 77.4M | - | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | 142M | 108M | 83.6M | 132M | 119M | 130M | 99.0M | - |
| Capital Expenditure | 40.0M | 38.2M | 25.8M | 16.7M | 22.5M | 33.7M | 38.7M | - |
| Ratios | ||||||||
| ROE | 7.3% | -0.6% | 4.4% | 10.0% | 22.1% | - | - | - |
| ROA | 2.4% | -0.2% | 1.6% | 3.9% | 12.4% | - | - | - |
| Net Profit Margin | 4.0% | -0.3% | 2.3% | 5.5% | 14.7% | - | - | - |
| Debt to Equity | 0.92x | 0.94x | 0.81x | 0.64x | 0.12x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Virbac SA dividends
Virbac SA has not paid dividends in the last 9 fiscal years.
Who owns Virbac SA
- Insiders 50.82%
- Institutions 25.80%
- Public & others 23.39%
- Free float 4.13M
Virbac SA company profile
- Company name
- Virbac SA
- Ticker
- 0NM7.LSE
- ISIN
- FR0000031577
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 6,442
- Fiscal year end
- December
- Address
- 13e rue LID - BP 27, Carros, France, 06511
- Phone
- 33 4 92 08 71 00
- Website
- corporate.virbac.com
About Virbac SA
Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, the United States, Brazil, and the Pacific. The company offers Vikaly, a cat food designed for the management of feline chronic kidney disease; Prevexto that contains imidacloprid and flumethrin, providing long-lasting parasite protection collar for dogs and cats at risk of fleas, ticks, lice, and sandflies; Zenidog/Zenifel offers a fogger, spray, and non-electric pheromone gel diffuser to soothe and reduce stress-related behaviors in dogs; Suigen Entero 3 is an inactivated vaccine aimed at preventing neonatal diarrhea in piglets caused by colibacillosis, clostridium, and rotavirus; Ursolyx soft chews formulated with ursolic acid that support muscle strength and mobility in dogs and cats; Zenifel a fogger and spray designed to reduce behaviors due to stress or undesirable behaviors in cats; Suigen PCV2 is a vaccine for porcine circovirus type 2; and Suigen Donoban is a multivalent vaccine used for the prevention of respiratory diseases in swine. It also provides a range of vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, immunology, nutrition, petfood, and pharmaceutical products. In addition, the company serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.
Virbac SA management
9- Mr. Paul MartingellChief Executive Officer · born 1981
- Mr. Habib RamdaniExecutive VP, Deputy CEO & CFO · born 1976
- Mr. Marc BistuerExecutive Vice President of Compliance · born 1962
- Mr. André MathieuExecutive Vice President of Operations
- Ms. Nathalie PolletExecutive Vice President of Global Marketing & Market Development
- Ms. Sophie FaviniExecutive Vice President of International Region
- Mr. Bertrand HavrileckExecutive Vice President of R&D
- Enguerrand DuboisExecutive Vice President of Europe Region
- Mr. Giovanni AbruzziniExecutive Vice President of North America Region